Jiangsu Shenji Biotechnology

Jiangsu Shenji Biotechnology Co., Ltd., operating as Synthgene Biotechnology, is a Chinese enterprise focused on providing foundational materials and services for the life sciences sector, with a specialization in nucleic acid-based technologies. Founded in July 2018 by Tong Kun and a team of chemical biology PhDs from Nanjing University, the company aims to resolve supply chain bottlenecks for critical raw materials in the biopharmaceutical industry. The founding team's deep technical background is complemented by the guidance of chief scientist Academician Hongyuan Chen.

Synthgene's business model is centered on the B2B manufacturing and supply of materials essential for mRNA and oligonucleotide drug development and production. The company generates revenue by selling these specialized products to pharmaceutical companies, contract research organizations (CROs), and other entities in the cell and gene therapy and in-vitro diagnostics (IVD) markets. Its clientele operates in a regulated environment, necessitating high-quality, compliant materials for their drug development and manufacturing processes.

The company's product portfolio is extensive, covering key components for the entire mRNA workflow. This includes a range of raw materials like nucleotides (NTPs), modified NTPs, and proprietary cap analogs, which are crucial for synthesizing stable and effective mRNA. To ensure quality and compliance for its clients, Synthgene maintains an ISO9001 certified quality system and has filed Drug Master Files (DMFs) with the U.S. FDA for its cGMP-grade raw materials. Beyond raw materials, the company has developed several technology platforms for antibody discovery, mRNA synthesis, LNP delivery, and oligonucleotide preparation. It also offers a suite of services, including analytical development, impurity detection kits, LNP screening, and process development for in-vitro transcription (IVT). For clients working on DNA and RNA synthesis, Synthgene provides high-quality phosphoramidites for cGMP oligo manufacturing.

Financially, the company has demonstrated significant growth, securing hundreds of millions in RMB through multiple funding rounds. It completed its A+ round co-led by Qingchi Capital and LYFE Capital, with continued participation from earlier investors like Sherpa Investment and Lenovo Star. This investment supports the firm's ongoing research and development efforts, which involve a team of over 200 R&D personnel. The company has been recognized as a potential unicorn enterprise in Nanjing, reflecting its strong position in addressing the localization and stable supply of biopharmaceutical raw materials in China. Keywords: mRNA raw materials, oligonucleotide manufacturing, nucleic acid chemistry, cGMP manufacturing, NTPs, cap analogs, phosphoramidites, LNP screening, IVT process development, cell and gene therapy, in-vitro diagnostics, biopharmaceutical supply chain, life sciences upstream solutions, Tong Kun, Nanjing University, analytical development services, drug master file, DNA synthesis, RNA synthesis, antibody discovery platform